Citi raised the firm’s price target on Arcturus Therapeutics (ARCT) to $49 from $47 and keeps a Buy rating on the shares. The firm believes the ARCT-032 Phase 2 readout in September offers a favorable risk/reward.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Optimistic Buy Rating for Arcturus Therapeutics Driven by Promising Developments in Cystic Fibrosis and COVID-19 Vaccine Programs
- Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress
- Arcturus Therapeutics reports Q2 EPS (34c), consensus (87c)
- Is ARCT a Buy, Before Earnings?
- Private Markets: Canva draws attention as IPO candidate following Figma debut